Yüklüyor......
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of ≥3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated wi...
Kaydedildi:
| Yayımlandı: | Oncol Lett |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734313/ https://ncbi.nlm.nih.gov/pubmed/26893783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.4069 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|